Bradley Pharmaceuticals, Inc. has agreed to development terms with Polymer Science, Inc. of Monticello, IN, a division of Marian, Inc. of Indianapolis, IN.

Polymer Science will develop delivery systems, not currently utilized by Bradley for future products to be commercialised by Bradley's Doak Dermatologics and Kenwood Therapeutics operating units.

The products to be developed and manufactured by Polymer Science for Bradley will be exclusive to Bradley and will be designed to help fill physician and patient needs for effective and convenient delivery of the active ingredients to be incorporated into these products. Product launches are expected in 2007 and beyond.

Bradley's initial financial commitment is $760,000, which is Polymer Science's estimate of its start-up costs associated with this project. According to the agreed upon payment schedule, Bradley will pay $190,000 in the Fourth Quarter 2006, followed by a second payment of $190,000 in the First Quarter 2007. The remaining $380,000 will be payable over the first three years of product production.

Polymer Science currently manufactures Trans Ver Sal, a salicylic acid wart removal patch system, marketed domestically by Doak Dermatologics as well as in 20 countries internationally.

Bradley President and CEO, Daniel Glassman, stated, "We are very pleased to expand our relationship with Polymer Science. Having enjoyed a successful collaboration on Trans Ver Sal, I am confident that this new project will be mutually beneficial as well."

Polymer Science President, Fred Ennis, stated, "We are excited to embark on this new phase of our relationship with Bradley. We believe that our expertise in delivery system technology will prove an invaluable asset to further enhance these successful Doak and Kenwood brands."